Hologic Inc. shares hit a fresh 52-week high of $76.07 Tuesday as the medical technology company's $18.3 billion buyout by private equity giants Blackstone and TPG appeared on track to close as early as April 7, leaving investors with a narrow window to decide whether to buy, sell or ride the deal to its likely conclusion.
The Nasdaq-listed stock (HOLX) closed Monday at $76.01, up 0.48% on heavy volume exceeding 102 million shares, trading essentially at the $76-per-share cash offer price spelled out in the October 2025 merger agreement. A non-tradable contingent value right, or CVR, could add up to $3 more per share if the company hits certain Breast Health revenue targets in fiscal 2026 and 2027.
